News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Antonious Z. Hazim: Honored to Have Led Study on ICI Pneumonitis in Lung Cancer Patients
Antonious Z. Hazim/X
May 11, 2025, 07:39

Antonious Z. Hazim: Honored to Have Led Study on ICI Pneumonitis in Lung Cancer Patients

Lung Cancer Europe shared a post by Antonious Z. Hazim, Hematology Medical Oncology Fellow at Mayo Clinic, Rochester Minnesota, on X, adding:

“A lot of recent discussion about ICI pneumonitis in lung cancer. This new study is an important step in understanding who’s most at risk, how to manage it, and when it might be safe to restart treatment. We often hear from people excluded from trials or left with limited options after serious ICI toxicity. More research like this helps protect access, reduce harm, and support better treatment decisions. Thanks Antonious Z. Hazim, Mayo Clinic.”

Quoting Antonious Z. Hazim‘s post

“ICI pneumonitis remains a significant challenge for our patients. Honored to have led this study. Thank you to my mentors.”

Title: Clinical characteristics, outcomes, and predictive modeling of patients diagnosed with immune checkpoint inhibitor therapy-related pneumonitis

Journal: Cancer Immunology, Immunotherapy

Authors: Antonious Hazim, Irene Riestra Guiance, Jacob Shreve, Gordon Ruan, Damian McGlothlin, Allison LeMahieu, Robert Haemmerle, Keith Mcconn, Richard C. Godby, Lisa Kottschade, Anna Schwecke, Casey Fazer-Posorske, Tobias Peikert, Eric Edell, Konstantinos Leventakos, Ashley Egan

Read Full Article.

ICI Pneumonitis

More posts about Lung Cancer on OncoDaily.

Allison LeMahieu Anna Schwecke Antonious Hazim Ashley Egan cancer Casey Fazer-Posorske Damian McGlothlin Eric Edell Gordon Ruan ICI Pneumonitis Irene Riestra Guiance Jacob Shreve Keith Mcconn Konstantinos Leventakos Lisa Kottschade Lung cancer OncoDaily Oncology Richard C. Godby Robert Haemmerle Tobias Peikert
Special Coverage
Blog
Jun 1, 2025, 04:58
Yan Leyfman: Excited to Present Research on GLP-1 Receptor Agonists at ASCO 2025
Blog
Jun 1, 2025, 04:53
Erika Hamilton: Highlights from Me at Day 2 of ASCO25
Oncolibrary
Jun 1, 2025, 04:52
BREAKWATER Trial: New Standard for BRAF V600E Metastatic Colorectal Cancer at ASCO 2025
Blog
Jun 1, 2025, 04:47
National Cancer Institute of Kenya - Major Breakthrough in Breast Cancer Treatment Costs in Kenya
Blog
Jun 1, 2025, 04:39
Guillermo Chantada: SIOP and ISOO Sign Agreement to Advance Retinoblastoma Care Globally
Opinion
Jun 1, 2025, 04:14
Every Trial Gives Hope: Tian Zhang Shared Reflections Ahead of ASCO 2025
Insight
Jun 1, 2025, 04:10
Paolo Tarantino: Impressive Phase 2 Data with the Trop2 ADC Sac-TMT for 1L mTNBC at ASCO 2025
Insight
Jun 1, 2025, 04:01
Kunal Jobanputra: Our Abstract on Metastatic Pancreatic Cancer in Western India Published in JCO
Oncolibrary
Jun 1, 2025, 03:54
POLCAGB Results at ASCO 2025: Concurrent Chemoradiation Plus Chemotherapy Improves Survival and Resection Outcomes in Locally Advanced Gallbladder Cancer
Oncolibrary
Jun 1, 2025, 03:54
INAVO120 Trial Final OS Analysis: INAVO Plus Palbociclib and Fulvestrant Improves Survival in PIK3CA-Mutated HR+/HER2– Advanced Breast Cancer
Career
Jun 1, 2025, 03:45
Enrique Soto: Honored to Receive the Conquer Cancer, the ASCO Foundation Advanced Clinical Research Award
Oncolibrary
Jun 1, 2025, 03:12
KEYNOTE-630 Phase 3 Trial at ASCO 2025: Adjuvant Pembrolizumab Does Not Significantly Improve Outcomes in High-Risk Resected Cutaneous Squamous Cell Carcinoma